Metabolite profiling in assessing ulcerative colitis activity: A systematic review

Abstract

Background

Ulcerative colitis (UC) is an immune-mediated chronic inflammatory condition of the colon, characterized by defects in the intestinal epithelial barrier, dysbiosis of the microbiota, and immune dysregulation. Metabolite profile has been widely and successfully used to characterize patient features in UC, as the development of metabolomics technology. Specific combinations of small metabolites can accurately depict the real-time pathological state of the body. Previous systematic reviews have focused on metabolite analysis between UC patients and healthy individuals, but have not systematically evaluated metabolite changes in different disease stages. This study focused on distinguish between patients in active and inactive phases, and even have the potential to predict changes in disease activity.

Aim

To summarize the distinct metabolites between the active and remission phases in serum and colonic mucosa in patients with UC.

Methods

A comprehensive literature search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, WanFang Data, and China National Knowledge Infrastructure from 1995 to 2022. Studies were selected which included metabolomics detection on serum or mucosal samples from patients with active or remission phase UC. The disease activity was assessed by using the Mayo score, Ulcerative colitis activity index score, or Geboes score. The risk of bias was assessed using the Newcastle-Ottawa Scale.

Results

Eleven articles (10 in English and 1 in Chinese) and 357 patients were included. Qualitative analysis was performed according to the classification of gas chromatography/mass spectrometry, liquid chromatography/mass spectrometry, or nuclear magnetic resonance. In the active period of UC, metabolites such as lipids, Amino acids showed a certain trend of change. Arachidonic acid showed specific upregulation in both serum and mucosal samples during the active stage in patients with UC.

Conclusion

There exists an association between metabolite profile and disease activity in patients with UC. Especially in patients with active UC, the lipid metabolite (arachidonic acid) is highly expressed simultaneously in the serum and mucosa. This finding will identify small molecule biomarkers that may potentially replace colonoscopy in the assessment and prediction of UC disease activity in the future, which indicates a significant potential for biomarker development.